July 2026—Labcorp announced that ColoSense, an FDA-approved, at-home test for colorectal cancer screening, is now available for adults ages 45 to 85 who are at average risk for developing CRC. The test uses RNA-based technology to detect biomarkers associated with colorectal cancer and advanced adenomas. It has a demonstrated sensitivity of 93 percent for colorectal cancer in average-risk individuals, 45 percent sensitivity for advanced adenomas, and 100 percent sensitivity for stage I colorectal cancer.
ColoSense is offered through a commercial collaboration with test developer Geneoscopy and covered for eligible Medicare and Medicare Advantage beneficiaries, following the Centers for Medicare and Medicaid Services update in June to the national coverage determination, with additional commercial coverage also available.
The test is not for people with a history of colorectal cancer or certain high-risk conditions and does not replace a diagnostic colonoscopy.
Labcorp, 336-229-1127